Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Launching of 2D Barcode Implementation on Pharmaceuticals Products and Starting the Pilot Phase in 2018

 
The Ministry of Public health has launched the pilot phase for 2D data Matrix Barcode Implementation on pharmaceutical products in the auditorium of the Ministry in Bir Hassan, under the patronage of Deputy Prime Minister Health Minister Ghassan Hasbani and in the presence of Director General of the Ministry Dr. Walid Ammar, the President of the Lebanese Order of Parmacists Georges Sili, the President of the Syndicate of Pharmaceutical Industries Caroline Abi Karam, the president of the Lebanese Pharmaceutical Importers Association Armond Phares, the President of the Syndicate of Hospital Owners Sleiman Haroun, the President of the Order of Physicians Raymond Sayegh, The Director of the Medical Care Directorate Dr. Joseph El-Helou, WHO representative Dr. Alissar Radi, Director of  E-Health program at the Ministry Lina Abou Mrad, and a number of representatives of hospitals and pharmaceutical industries.

The Director General Dr. Walid ammar explained the strategic frame of the project that comes within the Lebanese pharmaceutical sector reform and improvement plan. This project is achieved by reconsidering the legislations, regulating the registration and pricing of drugs, developing standards and programs to ensure quality in order to provide the patients with a safe quality-assured drug at the right price.

Mrs. Lina Abou Mrad then announced the launch of the implementation of 2D Barcode in 2018, while explaining the requirements of the information system that was lately developed to track the drugs across the supply chain, from manufacturing phase to sale to patients. Mrs Abou Mrad outlined as well the timeline for the implementation phase.

Hasbani

Hasbani said it was a pleasure to launch a new step for a long path of technology implementation to improve the performance of the healthcare sector. “Today we are launching the pilot phase for 2D barcode implementation that aims at ensuring the patient’s access to the safe drug, tracking drugs across the traceability supply chain, controlling illegal drugs and speeding up drugs recall from the Lebanese market and reimbursement of patients affiliated to insurers”, he added.
    1
    ...
ATC Name B/G Ingredients Dosage Form Price
A02AF02 ACTONORM B Aluminium hydroxide - 220mg/5ml, Magnesium hydroxide - 200mg/5ml, Simethicone - 25mg/5ml Suspension 425,998 L.L
R05CA ASPECTON COUGH SYRUP G Thyme soft extract - 6.69g/100ml Syrup 588,603 L.L
S01GA04 ALERJON G Oxymetazoline HCl - Drops solution 528,130 L.L
L01XK52 AKEEGA B Niraparib - 100mg, Abiraterone acetate - 500mg Tablet, film coated 519,366,124 L.L
L01XK52 AKEEGA B Niraparib - 50mg, Abiraterone acetate - 500mg Tablet, film coated 519,366,124 L.L
C09BB04 ANCAVAZ G Amlodipine - 5mg, Perindopril - 5mg Tablet, film coated 491,846 L.L
J01CR02 AMOXICLAV-ORBUCELL G Amoxicillin - 1g, Clavulanic Acid (potassium) - 0.2g Injectable powder for solution 7,433,691 L.L
C09BB04 ANCAVAZ G Amlodipine - 5mg, Perindopril - 10mg Tablet, film coated 669,234 L.L
C02LA51 ADELPHAN ESIDREX B Reserpine - 0.1mg, Hydrochlorothiazide - 10mg, Dihydralazine - 10mg Tablet 371,157 L.L
J01CR02 AMOKLAVIN BID 400/57MG FORTE G Amoxicillin (trihydrate) - 400mg/5ml, Clavulanic Acid (potassium) - 57mg/5ml Powder for suspension 278,175 L.L
J01CR02 AMOKLAVIN ES G Amoxicillin (trihydrate) - 600mg/5ml, Clavulanic Acid (potassium) - 42.9mg/5ml Powder for suspension 507,972 L.L
M05BB03 ACIDE ALENDRONIQUE/ VITAMINE D3 BGR G Alendronic acid - 70mg, Colecalciferol - 5600UI Tablet 815,712 L.L
S02CA06 AURICULARUM G Dexamethasone (sodium phosphate) - 10mg, Nystatin - 1,000,000IU, Oxytetracycline HCl - 90,000IU, Polymyxin B sulfate - 100,000IU Powder for suspension + solvent 755,239 L.L
R05DA20 ALGOMIEL COUGH SYRUP G Dextromethorphan HBr - 5mg, Carbinoxamine maleate - 2mg Syrup 639,925 L.L
J01CR02 AYECLAV-T G Amoxicillin - 875mg, Clavulanic Acid - 125mg Tablet 338,648 L.L
D07XC04 AZONIT - D G Diflucortolone valerate - 1mg/g, Isoconazole nitrate - 10mg/g Cream 225,766 L.L
V01AA ACARIZAX 12 SQ-HDM ORAL LYOPHILISATE B Allergen extracts - 12 SQ-HDM Tablet, lyophilised 9,366,451 L.L
C05A ANTROLIN B Nifedipine - 0.3%, Lidocaine - 1.5% Cream 1,333,092 L.L
R05X ACTISOUFRE B Sulfure de Sodium - 13mg, Saccharomyces Cerevisiae - 500mg Solution 740,457 L.L
R06AA52 AMYDRAMINE G Diphenhydramine HCl - 13.5mg/5ml, Sodium citrate - 57mg/5ml, Ammonium chloride - 131.5mg/5ml, Menthol - 1mg/5ml Syrup, sugar free 133,040 L.L
R06AB54 ALERGICAL EXPECTORANT B Chlorpheniramine maleate - 50mg/100ml, Guaifenesin - 2000mg/100ml, Dihydroxypropyltheophylline - 500mg/100ml, Paracetamol - 2000mg/100ml Syrup 485,127 L.L
N01BB58 ARTINIBSA 4% WITH EPINEPHRINE 1/100000 B Articaine HCl - 4%, Epinephrine - 1/100.000 Injectable solution 1,968,729 L.L
N01BB58 ARTICAINE MEDIS ADRENALINE G Articaine HCl - 40mg/ml, Adrenaline - 0.07mg/ml Injectable solution 1,881,380 L.L
V07AB01 ARWAN WFI G Water for injection - Water for injection, irrigation 399,915 L.L
J07BX05 ABRYSVO B RSV subgroup A stabilized perfusion F antigen 60mcg - 60mcg, RSV subgroup B stabilized perfusion F antigen 60mcg - 60mcg, Glycoprotein F stabilized in the perfusion conformation - Injectable powder + solvent 22,650,721 L.L
C09DA03 ARBITEN PLUS G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet 544,256 L.L
N02AJ06 ALGOCOD G Paracetamol - 500mg, Codeine phosphate - 30mg Tablet, effervescent 299,677 L.L
C09DA03 ARBITEN PLUS G Valsartan - 160mg, Hydrochlorothiazide - 25mg Tablet 579,196 L.L
N02AJ08 ASTEFOR G Ibuprofen - 400mg, Codeine phosphate hemihydrate - 30mg Tablet, film coated 935,314 L.L
C10BA05 ATOZET B Atorvastatin - 10mg, Ezetimibe - 10mg Tablet, film coated 1,624,706 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025